comprehensive -WSS

comprehensive

author：fashion 2025-10-03 00:03:55 - browse：3321

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Health care court cases: Humana, Sutter, Novant

focus

WSS

Health insurers say they are turning to AI to cut costs, improve care

ALS patient reclaims some autonomy thanks to wearable 'robot'

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Health insurers say they are turning to AI to cut costs, improve care

Adam's Biotech Scorecard: Do Sarepta's exon

Wikipedia

comprehensive

hotspot

Sports medicine is finally prioritizing gender equality

The system is set up to fail children with medical complexity

Novavax promises a turnaround & Lilly roils the obesity market

David Sabatini, ex

Duchenne breakthrough therapy leaves behind pioneering families

David Sabatini, ex

How to save PrEP access — and even expand it

Health care court cases: Humana, Sutter, Novant

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Akili, maker of video game for ADHD, to be acquired for 34 million

entertainment

Report captures long Covid’s disabling effects and policy challenges

NIH tests clinical research in primary care with $30 million program

Health insurers say they are turning to AI to cut costs, improve care

Study: Why relieving medical debt did not improve financial outcomes

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Heat waves linked to early deliveries, preterm births in new study

leisure time

focus

entertainment

leisure time